Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...
On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan ...
ECIM 2025 saw a heated discussion on whether anticoagulation in DVT should be treated like a chronic condition, as new ...
2don MSN
The Fukushima Daiichi nuclear power plant’s radiation levels have significantly dropped since the cataclysmic meltdown 14 ...
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
GlobalData on MSN9d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trialDaiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
Welcome to this day in history, March 13th.First and foremost, one of the most impactful global events occurred on March 13, 1969, when the United States, ...
BERKELEY, CA, USA I March 11, 2025 I Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, today ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
Fourteen years after the Fukushima Daiichi meltdown, radiation levels have decreased, but decommissioning efforts remain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback